tradingkey.logo
tradingkey.logo

Amgen's Repatha Cuts Risk Of First Major Cardiovascular Event By 31% In High-Risk Patients

ReutersMar 28, 2026 8:50 PM

- Amgen Inc AMGN.O:

  • AMGEN: PHASE 3 VESALIUS-CV CLINICAL TRIAL SHOWED REPATHA REDUCED RISKS OF HEART ATTACK, CORONARY HEART DISEASE DEATH, ISCHEMIC STROKE

  • AMGEN: REPATHA CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENT BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Source text: [ID:]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI